Introduction
Malignant gliomas are the most common primary brain tumors associated with a poor prognosis. More than 90% of patients experience local recurrence, and the 5-year survival rate is only 9%. 1 The growth and metastasis of a neoplasm depends on the formation of adequate vascular support. Angiogenesis is a rate-limiting step in the development of tumors, because tumor growth is generally limited to 1 to 2 mm 3 in the absence of a blood supply, and has a major role in tumor invasion, growth, and metastasis. 2 Gliomas are the most angiogenic human tumors, as characterized by proliferative vascular endothelial cells with high levels of cytokines such as basic fibroblastic growth factor (bFGF) and vascular endothelial cell growth factor (VEGF). The high expression levels of VEGF and bFGF contribute to the enhanced survival of tumor-associated endothelial cells and results in a certain level of tumor resistance to conventional therapies. [3] [4] [5] 
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This study provides important preclinical information and a mechanism for the clinical application of artemether to brain glioma therapy in the near future.
Materials and Methods

Growth Inhibition of Rat C6 Glioma Cells by Artemether
Rat C6 glioma cell growth was determined using the MTT quantitative colorimetric assay. 13 The cells were seeded at 1 × 10 5 cells/mL density and incubated with artemether at various concentrations (200, 100, 50, 25, 12.5, 6.25, and 3.125 µg/mL) for 24, 48, and 72 hours. Thereafter, the medium was changed, and cells were incubated with MTT (0.5 mg/mL) for 4 hours. The viable cell number is directly proportional to the production of formazan, which can be measured spectrophotometrically (λ = 570 nm). Cell growth was determined by counting the number of cells at indicated periods of time. To easily see the inhibitory effects of different artemether doses and different exposures on cell growth, inhibitory concentration 50% (IC50; an artemether dose required to cause 50% of cell viability loss) was calculated. Cellular proliferation inhibition rates are calculated as follows: Rate (%) = (1 − average A570nm value of experimental group/average A570nm value of control group) × 100%.
Animals and Cell Lines
Specific pathogen-free SD rats (6-8 weeks old and 200-250 grams in weight) were purchased from Kunming Medical College Animal Facility (Kunming, PR China). Housing and care of animals were consistent with the National Institute of Health Guide for Care and Use of Experimental Animals and approved by our animal care committee (# SCXK-Dian-P0005-0008).
Rat C6 glioma cell line was obtained from the Kunming Institute of Zoology, Chinese Academy of Sciences. Cells were grown at 37°C with 5% CO 2 in RPMI-1640 medium (GIBCO) supplemented with 10% FBS, 4 mM glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
Orthotopic Implantation of Tumor Cells
Orthotopic implantation of glioma cells was performed as described in an earlier article. 14 Briefly, SD rats (200-250 g) were anesthetized (0.3 mL/100 g). They were secured in a rodent stereotactic frame, the skin of the head was cleaned with iodine, and the skull was exposed after incision. A hollow guide screw was implanted into a small drill hole made 3 mm left lateral and 1 mm anterior to the bregma. C6 rat glioma cells (1 × 10 6 ) grown in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics were injected through the hollow guide screw into the white matter at a depth of 5 mm. After a waiting time of 2 minutes, the drilled hole was sealed with bone wax to prevent any reflux. The wound was sutured and covered with surgical glue. The whole procedure was performed under sterile conditions.
In Vivo Animal Experimental Design
To determine whether artemether could inhibit tumor growth, different dosages of artemether were orally administered to SD rats bearing C6 glioma cells. Forty animals were chosen and randomly assigned to 5 groups with 8 mice each. Group I treated with saline served as blank controls. Group II were orally administered artemether (Kunming, PR China, # 05106702) at a dosage of 33.3 mg/ kg once a day; group III, 50 mg/kg; group IV, 66.6 mg/kg; and group V, 50 mg/kg plus ferrous sulfate (Henan, PR China, # 05802) 1.5 mg/kg. Treatment began 3 days after tumor cell challenge and was continued for 10 days. The tumor volume was calculated by measuring the section with the largest tumor portion and applying the formula V (mm 3 ) = a2bπ/6, where a is the mean long path (mm) and b the mean short path (mm).
Histological and Immunohistochemistry Assay
All rats were killed 24 hours after the last treatment, and the tumor tissue was collected for the subsequent histology assay. Paraffin sections (5 µm) of tumor tissues were stained with hematoxylin and eosin. Immunohistochemistry was performed as described in an earlier article. 15 For CD31 staining, tissue sections were stained with each antibody for CD31 (BD Pharmingen). To quantify each immunostaining, the number of stained cells was counted in 10 random fields. The inhibitory effect on tumor growth was determined using the following formula: Percentage rate of tumor inhibition = ([1 − the average tumor volume of experimental groups]/the average tumor volume of control groups) × 100. 
Statistical Analysis
The statistical significance of differential data between experimental groups and controls was determined by ANOVA and an unpaired Student's t test. P < .05 was considered significant.
Results
Artemether Inhibits Rat C6 Brain Glioma Cell Growth in a Dose-and Time-Dependent Manner in Vitro
First, we studied the effect of artemether on cell growth. The cells were exposed to different doses of artemether (200, 100, 50, 25, 12.5, 6.25, 3.125 µg/mL) for 24, 48, and 72 hours and then subjected to MTT assays. As shown in Table 1 , a significant change in artemether-treated cells was seen in a dose-and time-dependent manner at the concentration range used (3.125 to 200 µg/mL; P < .01).
In comparison with the untreated control groups, the data on the rate of rat C6 brain glioma primary tumor growth and the mean tumor volume treatment with artemether in vivo showed that artemether had an inhibitory effect on tumor growth. However, the difference in the rate of tumor growth as well as the mean tumor volume between each experimental group was not significant (P > .05), with one exception-the difference for group V (artemether plus ferrous sulfate) was significant (P < .05; Table  2 ). We concluded that artemether had an inhibitory effect in vivo on tumor mass in the C6 glioma model in a doseindependent manner at the concentration range used (33.3-66.6 mg/kg daily; P > .05), and coadministration of ferrous sulfate and artemether could have synergistically inhibitory effects on animals with tumors.
Inhibition of in Vivo Angiogenesis by Treatment With Artemether
To further investigate the mechanism of antitumor effect of artemether on rat C6 brain gliomas, we evaluated the effect of this treatment on tumor angiogenesis. Our examination of paraffin-embedded tumor by immunohistochemistry using an anti-CD31 antibody that recognizes microvessel density (MVD) revealed an apparent decrease in tumor size in the artemether-treated groups as compared with the untreated group (Figure 1 ; P < .05, P < .01, respectively).
Discussion
Despite the current modalities of treatment, the prognosis for glioblastoma remains extremely poor. This emphasizes the need for optimizing therapy. The study of tumor-related angiogenesis was basically initiated by a new theory proposed by Folkman 16, 17 in 1971. It was suggested that without neovascularization, the growth of tumors is limited to a diameter of only a few millimeters, irrespective of whether the tumors are primary or secondary. The earliest angiogenic stages are defined by vasodilation and an increased vascular permeability of preexisting capillaries or postcapillary venules. This allows activated endothelial cells to migrate, and the matrix is locally degraded to allow underlying endothelial cells to migrate. The endothelial cells then multiply, loosely following each other into the perivascular space and forming a migration column. Therefore, there is much focus on the role of endothelial cells as targets for tumor management. 18, 19 As the clinical progression of glioblastoma correlates with its vascularization, the inhibition of tumor angiogenesis has emerged as a promising therapeutic strategy. 20 In the orthotopic rat C6 glioma model, in vivo oral administration of artemether reduced C6 brain glioma growth and remarkably decreased microvessel density in a dose-independent manner. One explanation may be related to why artemether was significantly effective against both P falciparum and cerebral malaria, that is, because of easy penetration of the blood-brain barrier, which might have good antiangiogenic effects on C6 brain gliomas and prevent tumor growth. 21, 22 Furthermore, our findings are in accord with our preliminary studies 12 that oral administration of artemether suppressed other types of cancer growth and remarkably reduced microvessel density at the range of dosage in vivo, which indicated that artemether suppressed tumor growth mainly via induction of antiangiogenesis. Thus artemether may be an ideal drug candidate for cancer prevention and treatment. Downregulation of VEGF expression by artemisinin analogs has been reported. 23 Further study will be needed to completely understand the mechanism of antiangiogenesis in artemether inhibition of C6 brain glioma growth in vivo.
In the present study, the efficacy of a combined treatment with artemether and ferrous sulfate in the inhibition of tumor growth in vivo was also investigated. Our data indicated that concurrent intake of an iron supplement may synergistically enhance the anticancer effects of artemether via iron metabolism. It has been shown that the mechanism through which artemisinin and its derivatives work in anticancer therapy might be, to some extent, similar to that in malaria therapy. The activities of all artemisinin derivatives depend on their internal endoperoxide bridge, and they work via highly reactive oxygenbased free radicals that become activated in the iron-rich red blood cell and kill the parasite in the process. Iron is required for cell division, and many cancer cells have larger numbers of iron-attracting transferrin receptors on their cell surface compared with normal cells. As a result, cancer cells have a much higher concentration of iron than normal cells do. Excessive free iron activates the artemisinin to generate a burst of free radicals that attack the iron-rich cell membrane, directly oxidizing some proteins or other macromolecules that play an important part in the tumor's rapid cell division, resulting in selective toxicity toward cancer cells. 7, 24, 25 Taken together, the findings in the present study demonstrate that artemether can significantly suppress rat C6 glioma growth at a range of dosages in a time-independent manner in vivo, mainly by penetrating the blood-brain barrier and inhibiting angiogenesis. Furthermore, concurrent intake of an iron supplement may synergistically enhance the anticancer effect of artemether. This suggests that it may provide an alternative method for brain glioma treatment.
